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Introduction
To date there are no head-to-head trials comparing the
efficacy of biologic treatments for polyarticular-course
JIA (pcJIA).
Objectives
To use statistical methods to estimate the relative effi-
cacy of biologic treatments, alone and in combination
with methotrexate (MTX), in the management of pcJIA
by means of indirect comparison of randomised con-
trolled trials (RCTs).
Methods
Based on a literature review, we identified RCTs of aba-
tacept, adalimumab (ADA), etanercept, infliximab and
tocilizumab (TCZ) in pcJIA. Comparative effectiveness
was estimated on the reported American College of
Rheumatology response rates (JIA ACR30/50/70/90)
measured at the end of the randomised, double-blind
phase by means of a Bayesian indirect comparison using
a fixed-effects ordered probit model. Probabilities of
achieving different levels of JIA ACR response were cal-
culated for biologic treatments and placebo using all
observed comparisons.
Results
The 5 RCTs identified showed differences in reporting JIA
ACR responses with regard to methods of non-responder
imputation during the blinded, controlled phase, allowing
only for the comparison of ADA and TCZ. In the base-
case analysis, for a JIA ACR30 placebo response of 31%,
TCZ monotherapy had a higher predicted probability of
JIA ACR30 (62%), JIA ACR50 (59%), JIA ACR70 (54%)
and JIA ACR90 (35%) response than ADA monotherapy
(53%, 49%, 44% and 26%, respectively). On MTX back-
ground therapy and a JIA ACR30 placebo response of
53%, ADA had a higher expected probability of response
at JIA ACR30 (76%), JIA ACR50 (75%), JIA ACR70 (66%)
and JIA ACR90 (49%) than TCZ (72%, 70%, 61% and 44%,
respectively). In neither monotherapy nor combination
therapy did differences between TCZ and ADA reach sta-
tistical significance. Differences in the study populations,
including previous use of biologics, were explored with
sensitivity analysis.
Conclusion
Based on JIA ACR response rates from this analysis, the
expected efficacy of ADA vs TCZ appears comparable
in pcJIA. These data should be interpreted in the con-
text of differences in the duration of the withdrawal
phase, which was shorter in the TCZ study (CHERISH)
than in the ADA trial and might have resulted in a
smaller difference in the number of flares observed
between placebo and TCZ. Differences in previous
exposure to biologics might also have affected the
results.
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